Protein S Ac is a reagent intended for the quantitative determination of the functional activity of protein S in human plasma. Protein Ca proteolytically cleaves F Va which is generated during the activation of the coagulation cascade by RVV (venom of Vipera russelli). In this reaction protein S acts as a cofactor which accelerates the reaction. As a result, the coagulation time increases proportionally to the activity of protein S in the sample. The addition of deficient plasma ensures that the test mixture has a sufficient supply of fibrinogen, Factor V and the other necessary coagulation factors. Coagulation is triggered at the level of Factor X by the FX activator of RVV. FXa forms thrombin from prothrombin under the action of the remaining Factor Va. The resulting thrombin finally converts fibrinogen to fibrin.

AI/ML Overview

Here's a breakdown of the requested information based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The document doesn't explicitly state "acceptance criteria" with pass/fail thresholds. Instead, it presents performance metrics against a predicate device and precision data. Thus, the table below reflects the reported performance which implies its acceptability for market clearance.

Metric (Implied Acceptance Criteria)	Reported Device Performance
Correlation Coefficient (vs. Predicate Device)	0.919
Slope (vs. Predicate Device)	0.961
Intercept (vs. Predicate Device)	+1.534
Within-series Variation (Normal Plasma)	3.6% - 5.1%
Day-to-day Variation (Normal Plasma)	2.0% - 4.1%
Total Precision (Normal Plasma)	4.6% - 5.5%
Within-series Variation (Deficient Plasma)	4.7% - 9.2%
Day-to-day Variation (Deficient Plasma)	1.9% - 7.7%
Total Precision (Deficient Plasma)	4.8% - 11.6%

2. Sample Size Used for the Test Set and Data Provenance

Sample Size: 239 patient samples
Data Provenance: The document does not specify the country of origin. It can be inferred as retrospective, as it refers to "patient samples" that were already collected and tested for comparison.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications

This information is not provided in the document. The comparison is made against a predicate device's results, not an independent expert-established ground truth.

4. Adjudication Method for the Test Set

This information is not provided in the document. Given the comparative nature with a predicate device, it's unlikely an adjudication method for ground truth was used in the traditional sense. The predicate device's results served as the reference.

5. Multi Reader Multi Case (MRMC) Comparative Effectiveness Study

This information is not applicable as the device is an in-vitro diagnostic (IVD) reagent for quantitative determination, not an imaging or AI-assisted diagnostic tool that involves human readers. Therefore, no effect size of human reader improvement with AI assistance is mentioned.

6. Standalone Performance (Algorithm only without human-in-the-loop performance)

The device, "Protein S Ac," is a reagent for quantitative determination. Its performance is inherently "standalone" in that it produces a result based on its chemical reactions and instrument measurement, without a human in the loop interpreting the result for diagnosis within the testing process itself. The presented precision and correlation data represent the standalone performance of the reagent and associated instrument (Sysmex CA 1500).

7. Type of Ground Truth Used

The "ground truth" for the comparative study was the results obtained from the predicate device, STA® Staclot® Protein S kit (K913424).

8. Sample Size for the Training Set

This information is not provided in the document. The document describes a performance evaluation of the final product, not the development or training of a model.

9. How the Ground Truth for the Training Set Was Established

This information is not provided because the document does not discuss a training set or the development of a predictive model that would require such training. The provided text focuses on the performance of a reagent against an existing predicate device.

Summary

{0}------------------------------------------------

K02290

Dade Behring Inc Protein S AC, K022290 Response to Questions

AUG 2 7 2002

Summary of Safety and Effectiveness Information

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

Submitter's Name:	Donna A. WolfDade Behring Inc.P.O. Box 6101Newark, DE 19714-6101
Date of Preparation:	August 7, 2002
Name of Product:	Protein S Ac
FDA Classification Name:	Factor Deficiency Test
Predicate Device:	STA® Staclot® Protein S kit (K913424)

Device Description:

Protein S Ac is a reagent intended for the quantitative determination of the functional activity of protein S in human plasma.

Protein Ca proteolytically cleaves F Va which is generated during the activation of the coagulation cascade by RVV (venom of Vipera russelli). In this reaction protein S acts as a cofactor which accelerates the reaction. As a result, the coagulation time increases proportionally to the activity of protein S in the sample. The addition of deficient plasma ensures that the test mixture has a sufficient supply of fibrinogen, Factor V and the other necessary coagulation factors.

Coagulation is triggered at the level of Factor X by the FX activator of RVV. FXa forms thrombin from prothrombin under the action of the remaining Factor Va. The resulting thrombin finally converts fibrinogen to fibrin.

Intended Use: For the quantitative determination of the functional activity of protein S in human plasma.

Comparison to Predicate Device:

Conclusion:

Split sample comparison between the Protein S Ac and the STA® StaClot® Protein S kit (K913424) gave a correlation coefficient of 0.919, slope of 0.961, and an intercept of +1.534 when tested with 239 patient samples spanning the range of the target population.

For normal plasma samples measured using the Sysmex® CA 1500, the resulting variation coefficients ranged between 3.6% and 5.1% within the series of measurements, and between 2.0% and 4.1% from day to day. Total precision ranged from 4.6 to 5.5%. For pathologically deficient plasma samples which were measured using the Sysmex® CA 1500, the resulting variation coefficients ranged between 4.7% and 9.2% within the series of measurements, and between 1.9% and 7.7% from day to day. Total precision ranged from 4.8 to 11.6%.

{1}------------------------------------------------

Image /page/1/Picture/1 description: The image is a black and white seal for the Department of Health & Human Services - USA. The seal is circular with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is a stylized image of three faces in profile, with three lines above them that resemble wings or feathers.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

AUG 27 2002

Ms. Donna Wolf Senior Regulatory Affairs Specialist Dade Behring, Inc. 514 GBC Drive Newark, Delaware 19702

K022290 Trade/Device Name: Protein S Ac Regulation Number: 21 CFR § 864.7290 Regulation Name: Factor Deficiency Test Regulatory Class: II Product Code: GGP Dated: July 12, 2002 Received: July 13, 2002

Dear Ms. Wolf:

Re:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{2}------------------------------------------------

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Autman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

Dade Behring Inc. Protein S AC, K022290 Response to Questions

Indications For Use Statement

Device Name: Protein S Ac

Indications for Use:

Reagent for the quantitative determination of the functional activity of protein S in human plasma.

Josephine Bautista

(Division Sign Division of Clinical Laboratory Devices

510(k) Number K022290

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use
(Per 21 CFR 801.109)

Over-the-counter Use

(Optional format 1-2-96)

Regulation Number and Section

§ 864.7290 Factor deficiency test.

(a)
Identification. A factor deficiency test is a device used to diagnose specific coagulation defects, to monitor certain types of therapy, to detect coagulation inhibitors, and to detect a carrier state (a person carrying both a recessive gene for a coagulation factor deficiency such as hemophilia and the corresponding normal gene).(b)
Classification. Class II (performance standards).